---
title: "Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295926228.md"
description: "In Toronto on August 14, 2026, Quantum BioPharma Ltd. (QNTM) released its financial and operational performance for the second quarter of 2026, concluding on June 30."
datetime: "2026-08-14T11:02:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295926228.md)
  - [en](https://longbridge.com/en/news/295926228.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295926228.md)
generator: "portal-rs"
---

# Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

In Toronto on August 14, 2026, Quantum BioPharma Ltd. (QNTM) released its financial and operational performance for the second quarter of 2026, concluding on June 30.

### Related Stocks

- [QNTM.US](https://longbridge.com/en/quote/QNTM.US.md)

## Related News & Research

- [Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2](https://longbridge.com/en/news/296129489.md)
- [Quantum Biopharma Provides Corporate Update](https://longbridge.com/en/news/296658147.md)
- [PicS Q2 2026 Earnings Preview](https://longbridge.com/en/news/296709997.md)
- [Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves](https://longbridge.com/en/news/296514765.md)
- [Xcel Energy sets BRL 0.26 per unit distribution for payment Oct. 26, 2026](https://longbridge.com/en/news/296646864.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**